RIYADH: The Kingdom’s Ministry of Health recently held an accelerator program in Boston to support the work of eight Saudi Arabia biotechnology and life sciences startups.
The first cohort of the program, carried out in partnership with BioLabs, had direct exposure to advanced global research and development environments, the ministry said in a statement.
It is a milestone in the Kingdom’s efforts to localize health innovation and strengthen its biotechnology and life sciences ecosystem, the ministry added.
The startups include Plansulin that is developing plant-based insulin, cellNUA offering nano-therapies derived from bees, SAGEbio focusing on next-generation vaccines, and Novo Genomics working on precision diagnostics.
In addition, MammoStem explores regenerative medicine, NanoPalm targets genetic disorders, KaRama Bio specializes in early disease detection, and PhageTech is working to combat antibiotic resistance.
Throughout the accelerator, the startups engaged with international experts, investors and strategic partners, gaining insights into regulatory frameworks, commercialization pathways, and scalable business models.
The closing week featured workshops and bilateral meetings focused on enhancing the companies’ operational, technical and investment readiness.
The companies progressed through advanced assessment stages over seven months.
They received tailored advisory support to refine research strategies, strengthen regulatory compliance, and develop commercialization roadmaps from laboratory settings to healthcare markets.
The ministry said the accelerator will help to support local content development, improve the competitiveness of Saudi Arabia’s health economy, and attract high-value investment opportunities.
The initiative aligns with the Health Sector Transformation Program under Vision 2030 and reflects the Kingdom’s broader ambition to position itself as a regional and global hub for biotechnology and life sciences innovation.
